Premium
Comparison between a serotonin and a noradrenaline reuptake blocker in the treatment of depressed outpatients Biochemical aspects
Author(s) -
Nyström C.,
Ross S. B.,
Hällström T.,
Kelder D.
Publication year - 1986
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1986.tb10578.x
Subject(s) - maprotiline , reuptake inhibitor , reuptake , serotonin , medicine , endocrinology , psychology , depression (economics) , pharmacology , antidepressant , receptor , macroeconomics , hippocampus , economics
— Seventy‐five outpatients with major depressive disorder (RDC) were randomly referred to treatment with a dominant 5‐HT reuptake blocker (zimeldine, 100 mg b.i.d.) or a dominant NA reuptake blocker (maprotiline 75 mg b.i.d.). Pretreatment biochemical, pharmacodynarnic and pharrnacokinetic variables were studied and related to the treatment outcome with the two drugs. Female responders to the dominant 5‐HT reuptake blocker were characterized by low pretreatment accumulation of 14 C‐5‐HT in rat synaptosomes, when incubated in patient plasma. Among zimeldine responders there was a relationship between antidepressive effect and steady‐state concentrations of zimeldine and norzimeldine. These findings support the hypothesis of a subgroup of depression characterized by serotonin disturbance.